Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Oct 8;5(1):2100100. doi: 10.1002/adtp.202100100

Figure 5.

Figure 5.

A decrease in marrow LSCs is observed via TBP-NP mediated delivery of MCL-64. A) Schematic and treatment for free MCL-64 and TBP-NP loaded MCL-64, B) bcCML mouse survival after treating with saline, free MCL-64, and TBP-NP loaded MCL-64. Data represents n = 10 per group. *p < 0.05 represents statistical analysis comparing free MCL-64 to MCL-64 in TBP-NPs performed using log-rank (Mantel-cox) test. C) GFP+ bcCML cells, D) LSC cells, E) LSK cells, and F) LT-HSCs in the marrow after free MCL-64 and TBP-NP loaded MCL-64 treatment. Data represents mean ± SD (n = 4–5). *p < 0.05 represents statistical differences comparisons using unpaired t-tests.